{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:49Z","timestamp":1740144229084,"version":"3.37.3"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2017YFC0909800"],"award-info":[{"award-number":["2017YFC0909800"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81830005"],"award-info":[{"award-number":["81830005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2016-I2M-1-001"],"award-info":[{"award-number":["CIFMS 2016-I2M-1-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chimeric antigen receptor-modified T-cell (CART) therapy has revolutionized the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). However, the capacity of CART therapy has not yet been fully elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>An 18-year-old Chinese male patient presented with multiple firm masses on the skin all over his body following regular chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Bone marrow smear and skin biopsy confirmed that it was a bone marrow and skin relapse from the initial B-cell ALL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>CD19 CART-cell therapy was performed to manage the bone marrow and skin of the relapsed B-cell ALL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>During CART-cell therapy, cytokine release syndrome and central nervous encephalopathy occurred. Eventually, the lesions disappeared, and the bone marrow and skin tested minimal residual disease (MRD) negative. The patient achieved complete remission (CR). Fourteen days after testing MRD negative, he received allogeneic hematopoietic stem-cell transplantation and has remained disease free to date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The CR of this patient with leukemia cutis demonstrated that CART exhibited efficacy in this case. While further research is still required, this treatment could potentially be used as a therapy for skin leukemia, lymphoma, and other primary skin cancers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018639","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T03:35:02Z","timestamp":1588390502000},"page":"e18639","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"99","author":[{"given":"Mianzeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benfa","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2016.09.001","article-title":"BCR-ABL (Ph)-like acute leukemia-pathogenesis, diagnosis and therapeutic options","volume":"31","author":"Ofran","year":"2017","journal-title":"Blood Rev"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMc1412123","article-title":"Ph-like acute lymphoblastic leukemia in older adults","volume":"371","author":"Herold","year":"2014","journal-title":"N Engl J Med"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.beha.2017.07.003","article-title":"The biology of Philadelphia chromosome-like ALL","volume":"30","author":"Roberts","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"90521","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/jamaoncol.2018.1915","article-title":"Progress and innovations in the management of adult acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.beha.2017.07.009","article-title":"The what, when and how of CAR T cell therapy for ALL","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.21037\/atm.2018.05.35","article-title":"The promise and challenges of chimeric antigen receptor T cells in relapsed B-cell acute lymphoblastic leukemia","volume":"6","author":"Ding","year":"2018","journal-title":"Ann Transl Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.18632\/oncotarget.7079","article-title":"Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells","volume":"7","author":"An","year":"2016","journal-title":"Oncotarget"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1298375","DOI":"10.1155\/2016\/1298375","article-title":"Mixed phenotype acute leukemia presenting as leukemia cutis","volume":"2016","author":"Narayanan","year":"2016","journal-title":"Case Rep Med"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3346\/jkms.2013.28.4.614","article-title":"Clinical characteristics of 75 patients with leukemia cutis","volume":"28","author":"Kang","year":"2013","journal-title":"J Korean Med Sci"},{"issue":"(Suppl 1)","key":"R16-20230915","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12288-015-0597-z","article-title":"Aleukemic leukemia cutis presenting as a sole sign of relapsed paediatric acute lymphoblastic leukemia","volume":"32","author":"Joshi","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1590\/abd1806-4841.20164557","article-title":"Bullous leukemia cutis mimicking facial cellulitis","volume":"91","author":"Caldato Lde","year":"2016","journal-title":"An Bras Dermatol"},{"key":"R19-20230915","first-page":"334","article-title":"Mixed phenotypic acute leukemia with leukemia cutis and neuroleukemiosis","volume":"30","author":"Poikayil","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2147\/TCRM.S146309","article-title":"The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL","volume":"14","author":"Forsberg","year":"2018","journal-title":"Ther Clin Risk Manag"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:57:09Z","timestamp":1694818629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018639"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":22,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018639","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}